Study of Lopinavir/Ritonavir Tablets Versus Soft Gel Capsules and Once Daily Versus Twice Daily Administration, When Coadministered With Nucleoside Reverse Transcriptase Inhibitors in Antiretroviral Naive Human Immunodeficiency Virus Type 1 Infected Subjects
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Daniel E Cohen, MD
Abbott
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
129 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Site Reference Id/investigator# 244
Darlinghurst, Australia
- Site Reference Id/investigator# 245
Melbourne, Australia
- Site Reference Id/investigator# 246
South Yarra, Australia
- Site Reference Id/investigator# 234
Antwerp, Belgium
- Site Reference Id/investigator# 235
Brussels, Belgium
- Site Reference Id/investigator# 233
Ghent, Belgium
- Site Reference Id/investigator# 236
Leuven, Belgium
- Site Reference Id/investigator# 225
Liège, Belgium
- Site Reference Id/investigator# 175
Calgary, Canada
- Site Reference Id/investigator# 184
Hamilton, Canada
- Site Reference Id/investigator# 176
Montreal, Canada
- Site Reference Id/investigator# 177
Montreal, Canada
- Site Reference Id/investigator# 179
Montreal, Canada
- Site Reference Id/investigator# 173
Ottawa, Canada
- Site Reference Id/investigator# 181
Ottawa, Canada
- Site Reference Id/investigator# 178
Ste-Foy, Canada
- Site Reference Id/investigator# 174
Toronto, Canada
- Site Reference Id/investigator# 180
Toronto, Canada
- Site Reference Id/investigator# 182
Toronto, Canada
- Site Reference Id/investigator# 172
Vancouver, Canada
- Site Reference Id/investigator# 183
Vancouver, Canada
- Site Reference Id/investigator# 294
Brno, Czechia
- Site Reference Id/investigator# 296
Pilsen, Czechia
- Site Reference Id/investigator# 286
Aix-en-Provence, France
- Site Reference Id/investigator# 275
Besançon, France
- Site Reference Id/investigator# 256
Lyon, France
- Site Reference Id/investigator# 278
Montpellier, France
- Site Reference Id/investigator# 257
Paris, France
- Site Reference Id/investigator# 279
Paris, France
- Site Reference Id/investigator# 280
Paris, France
- Site Reference Id/investigator# 281
Paris, France
- Site Reference Id/investigator# 284
Paris, France
- Site Reference Id/investigator# 274
Rennes, France
- Site Reference Id/investigator# 282
Vandœuvre-lès-Nancy, France
- Site Reference Id/investigator# 265
Berlin, Germany
- Site Reference Id/investigator# 270
Berlin, Germany
- Site Reference Id/investigator# 262
Bochum, Germany
- Site Reference Id/investigator# 268
Bonn, Germany
- Site Reference Id/investigator# 271
Cologne, Germany
- Site Reference Id/investigator# 266
Frankfurt, Germany
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 30 Nov 2005
- Primary completion
- 31 Jul 2008
- Completion
- 31 Jul 2008
- Last update posted
- 6 Feb 2012
- Registered enrollment
- 664
- Registry id
- NCT00262522
Cross-registrations
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.